OX2R Inhibitors
3 drugsAbout OX2R
Orexin receptor 2 (OX2R) is a G protein-coupled receptor that regulates wakefulness and sleep. Targeting OX2R modulates neuronal signaling to address sleep disorders.
OX2R is a therapeutic target for sleep disorders, but currently, there is no genetic evidence directly linking OX2R to specific diseases.
Three FDA-approved drugs, DAYVIGO, QUVIVIQ, and BELSOMRA, target OX2R, all of which are small molecules. These drugs are marketed by EISAI INC, IDORSIA, and Merck, respectively, for sleep-related conditions.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Delayed Sleep Phase Syndrome with only 2 trials.
Top OX2R Drugs
The OX2R drug market is dominated by three companies: EISAI INC, IDORSIA, and Merck.
High market concentration suggests significant barriers to entry for new competitors.
OX2R Drug Modality Landscape
Modalities
Routes of Administration
OX2R is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
OX2R Clinical Trials 119 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 29 | 28 | 0 | 1 | 100% |
| Phase 2 | 37 | 15 | 5 | 17 | 75% |
| Phase 3 | 17 | 14 | 0 | 3 | 100% |
| Phase 4 | 36 | 19 | 4 | 13 | 83% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved OX2R drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting OX2R. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
OX2R Drug Approval Timeline (2014 - 2022)
The first OX2R-targeting drug was approved in 2014, with the most recent approval in 2022.
Relatively recent approvals suggest continued interest in OX2R as a therapeutic target, but the market may be approaching saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 104 clinical trials targeting OX2R.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities